Does TAFAMIDIS MEGLUMINE Cause Hyperlipidaemia? 16 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Hyperlipidaemia have been filed in association with TAFAMIDIS MEGLUMINE (Vyndaqel). This represents 0.4% of all adverse event reports for TAFAMIDIS MEGLUMINE.
16
Reports of Hyperlipidaemia with TAFAMIDIS MEGLUMINE
0.4%
of all TAFAMIDIS MEGLUMINE reports
1
Deaths
14
Hospitalizations
How Dangerous Is Hyperlipidaemia From TAFAMIDIS MEGLUMINE?
Of the 16 reports, 1 (6.3%) resulted in death, 14 (87.5%) required hospitalization.
Is Hyperlipidaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TAFAMIDIS MEGLUMINE. However, 16 reports have been filed with the FAERS database.
What Other Side Effects Does TAFAMIDIS MEGLUMINE Cause?
Death (1,196)
Cardiac failure (519)
Off label use (418)
Dyspnoea (227)
Product use in unapproved indication (202)
Cardiac failure chronic (188)
Atrial fibrillation (164)
Fatigue (163)
Disease progression (157)
Condition aggravated (144)
What Other Drugs Cause Hyperlipidaemia?
ALENDRONATE (511)
AMLODIPINE (226)
DENOSUMAB (204)
SITAGLIPTIN (186)
METHOTREXATE (184)
ROSUVASTATIN (179)
PREDNISONE (169)
FINASTERIDE (145)
MYCOPHENOLATE MOFETIL (141)
ASPIRIN (138)
Which TAFAMIDIS MEGLUMINE Alternatives Have Lower Hyperlipidaemia Risk?
TAFAMIDIS MEGLUMINE vs TAFASITAMAB
TAFAMIDIS MEGLUMINE vs TAFASITAMAB-CXIX
TAFAMIDIS MEGLUMINE vs TAFINLAR
TAFAMIDIS MEGLUMINE vs TAFLUPROST
TAFAMIDIS MEGLUMINE vs TAGRAXOFUSP-ERZS